JP4514455B2 - Ｔｎｐ−４７０ポリマー複合体及びその使用 - Google Patents

Ｔｎｐ−４７０ポリマー複合体及びその使用 Download PDF

Info

Publication number
JP4514455B2
JP4514455B2 JP2003583402A JP2003583402A JP4514455B2 JP 4514455 B2 JP4514455 B2 JP 4514455B2 JP 2003583402 A JP2003583402 A JP 2003583402A JP 2003583402 A JP2003583402 A JP 2003583402A JP 4514455 B2 JP4514455 B2 JP 4514455B2
Authority
JP
Japan
Prior art keywords
tnp
tumor
polymer
complex
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2003583402A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005529870A (ja
JP2005529870A5 (enExample
Inventor
ロニット スタチ−ファイナロ
ユダ フォークマン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston Childrens Hospital
Original Assignee
Boston Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Childrens Hospital filed Critical Boston Childrens Hospital
Publication of JP2005529870A publication Critical patent/JP2005529870A/ja
Publication of JP2005529870A5 publication Critical patent/JP2005529870A5/ja
Application granted granted Critical
Publication of JP4514455B2 publication Critical patent/JP4514455B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L53/00—Compositions of block copolymers containing at least one sequence of a polymer obtained by reactions only involving carbon-to-carbon unsaturated bonds; Compositions of derivatives of such polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/18—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
    • C07D303/20—Ethers with hydroxy compounds containing no oxirane rings
    • C07D303/22—Ethers with hydroxy compounds containing no oxirane rings with monohydroxy compounds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F220/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride ester, amide, imide or nitrile thereof
    • C08F220/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
    • C08F220/52—Amides or imides
    • C08F220/54—Amides, e.g. N,N-dimethylacrylamide or N-isopropylacrylamide
    • C08F220/56—Acrylamide; Methacrylamide
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F220/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride ester, amide, imide or nitrile thereof
    • C08F220/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
    • C08F220/52—Amides or imides
    • C08F220/54—Amides, e.g. N,N-dimethylacrylamide or N-isopropylacrylamide
    • C08F220/58—Amides, e.g. N,N-dimethylacrylamide or N-isopropylacrylamide containing oxygen in addition to the carbonamido oxygen, e.g. N-methylolacrylamide, N-(meth)acryloylmorpholine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2003583402A 2002-04-11 2003-04-10 Ｔｎｐ−４７０ポリマー複合体及びその使用 Expired - Fee Related JP4514455B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37179102P 2002-04-11 2002-04-11
US41470502P 2002-09-30 2002-09-30
PCT/US2003/010976 WO2003086382A1 (en) 2002-04-11 2003-04-10 Tnp-470 polymer conjugates and use thereof

Publications (3)

Publication Number Publication Date
JP2005529870A JP2005529870A (ja) 2005-10-06
JP2005529870A5 JP2005529870A5 (enExample) 2006-04-13
JP4514455B2 true JP4514455B2 (ja) 2010-07-28

Family

ID=29254460

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003583402A Expired - Fee Related JP4514455B2 (ja) 2002-04-11 2003-04-10 Ｔｎｐ−４７０ポリマー複合体及びその使用

Country Status (7)

Country Link
US (5) US7332523B2 (enExample)
EP (1) EP1494662B1 (enExample)
JP (1) JP4514455B2 (enExample)
AU (2) AU2003230852B2 (enExample)
CA (1) CA2480666C (enExample)
ES (1) ES2398381T3 (enExample)
WO (1) WO2003086382A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030100605A1 (en) * 2001-05-15 2003-05-29 Grupp Stephan A. Methods of treating cancer with angiogenesis inhibitors
WO2003086178A2 (en) * 2002-04-11 2003-10-23 Children's Medical Center Corporation Methods for inhibiting vascular hyperpermeability
ES2398381T3 (es) * 2002-04-11 2013-03-15 Children's Medical Center Corporation Conjugados del copolímero de ácido metacrílico-hpma-tnp-470 y sus usos
US20080248030A1 (en) * 2005-02-02 2008-10-09 Children's Medical Center Corporation Method of Treating Angiogenic Diseases
EP1919882A2 (en) 2005-02-17 2008-05-14 Synta Pharmaceuticals Corporation Isoxazole combretastatin derivatives for the treatment of proliferative disorders
EP2170402B1 (en) 2007-06-26 2015-03-25 Children's Medical Center Corporation Metap-2 inhibitor polymersomes for therapeutic administration
WO2009036108A1 (en) * 2007-09-13 2009-03-19 Children's Medical Center Corporation Methods and compositions for inhibiting vascular leakage
WO2009049089A1 (en) 2007-10-09 2009-04-16 Washington University In St. Louis Ligand directed toroidal nanoparticles for therapy and diagnostic imaging
US9446150B2 (en) 2007-10-09 2016-09-20 Washington University Particles for imaging
EA020251B1 (ru) * 2007-11-28 2014-09-30 Мерсана Терапьютикс, Инк. Биосовместимые и биоразлагаемые конъюгаты аналогов фумагиллина
EP2307032A4 (en) * 2008-05-22 2014-08-20 Univ Ramot NEW CONJUGATES OF POLYMERS WITH A THERAPEUTIC AGENT AND AN ANGIOGENESIS TARGETING PART CONTAINED THEREOF, AND USES IN THE TREATMENT OF DISEASES ASSOCIATED WITH ANGIOGENESIS
US8658149B2 (en) 2008-05-22 2014-02-25 Ramot At Tel-Aviv University Ltd. Conjugates of a polymer, a bisphosphonate and an anti-angiogenesis agent and uses thereof in the treatment and monitoring of bone related diseases
US8703114B2 (en) 2008-05-22 2014-04-22 Ramot At Tel-Aviv University Ltd. Conjugate of a polymer, an anti-angiogenesis agent and a targeting moiety, and uses thereof in the treatment of bone related angiogenesis conditions
US8715685B2 (en) * 2009-07-14 2014-05-06 Lucia Irene Gonzalez Stereoisomer peptides and their polymer conjugates for HIV disease
US8715986B2 (en) * 2009-10-29 2014-05-06 Lucia Irene Gonzalez Stereoisomer peptides, ligand-targeted multi- stereoisomer peptide polymer conjugates, and uses thereof
WO2011084700A1 (en) 2009-12-17 2011-07-14 The Washington University Antithrombotic nanoparticle
US9808500B2 (en) 2009-12-17 2017-11-07 Washington University Antithrombotic nanoparticle
AU2011239414A1 (en) 2010-04-15 2012-11-08 The Washington University Prodrug compositions, prodrug nanoparticles, and methods of use thereof
US20110294952A1 (en) * 2010-05-25 2011-12-01 SynDevRX Optimized Drug Conjugates
US9895449B2 (en) * 2010-05-25 2018-02-20 Syndevrx, Inc. Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof
US9320805B2 (en) * 2010-05-25 2016-04-26 Syndevrx, Inc. Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof
EP2822598A4 (en) 2012-03-05 2016-04-13 Univ Ramot POLYMERS HAVING THERAPEUTICALLY ACTIVE AGENTS CONJUGATED THERETO, METHODS FOR THE PREPARATION OF SAID POLYMERS AND USES THEREOF
BR112015025892A2 (pt) 2013-04-10 2017-07-25 Syndevrx Inc inibidores de metap2 e métodos para tratar obesidade
EP3020114B1 (en) 2013-07-11 2017-05-17 General Electric Company Grid power factor control system
TW201636342A (zh) 2014-12-19 2016-10-16 武田藥品工業有限公司 煙黴醇衍生物
KR102849342B1 (ko) 2015-12-10 2025-08-21 신데브알엑스, 인크. 푸마길롤 유도체 및 그의 다형체
KR20180100663A (ko) 2016-01-11 2018-09-11 신데브알엑스, 인크. 대사 기능장애에 의하여 유도된 종양에 대한 치료
KR20200096939A (ko) * 2017-12-06 2020-08-14 제넨테크, 인크. 면역조직화학을 위한 합성 대조군
JP2022512826A (ja) 2018-10-26 2022-02-07 シンデブルックス，インコーポレイティド ＭｅｔＡＰ２阻害剤のバイオマーカーとその応用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8500209D0 (en) 1985-01-04 1985-02-13 Ceskoslovenska Akademie Ved Synthetic polymeric drugs
US5164410A (en) 1988-01-09 1992-11-17 Takeda Chemical Industries, Ltd. Fumagillol derivatives and pharmaceutical compositions thereof
EP0359036B1 (en) 1988-09-01 1997-03-26 Takeda Chemical Industries, Ltd. Fumagillol derivatives
US5166172A (en) 1988-09-01 1992-11-24 Takeda Chemical Industries, Ltd. Fumagillol derivatives and pharmaceutical compositions thereof
US5180738A (en) 1988-09-01 1993-01-19 Takeda Chemical Industries Fumagillol derivatives and pharmaceutical compositions thereof
US5290807A (en) 1989-08-10 1994-03-01 Children's Medical Center Corporation Method for regressing angiogenesis using o-substituted fumagillol derivatives
US6017954A (en) 1989-08-10 2000-01-25 Children's Medical Center Corp. Method of treating tumors using O-substituted fumagillol derivatives
EP0415294A3 (en) 1989-08-31 1991-06-12 Takeda Chemical Industries, Ltd. Cyclohexanol derivatives, production and use thereof
EP0889041B1 (en) 1996-03-06 2002-07-24 TSUMURA & CO. Novel iridoid derivatives and neovascularization inhibitors containing the same as active ingredient
US6225478B1 (en) 1997-03-05 2001-05-01 Tsumura & Co. Iridoid derivatives and neovascularization inhibitors containing the same as active ingredient
WO2001036002A1 (en) * 1999-11-17 2001-05-25 School Of Pharmacy, University Of London Conjugates of hpma copolymer and ellipticin
WO2001097776A1 (fr) * 2000-06-22 2001-12-27 Takeda Chemical Industries, Ltd. Composition médicamenteuse contenant un polymère
ATE552859T1 (de) * 2000-09-13 2012-04-15 Praecis Pharm Inc Pharmazeutische formulierungen zur kontinuierlichen abgabe von peptiden
US6548477B1 (en) * 2000-11-01 2003-04-15 Praecis Pharmaceuticals Inc. Therapeutic agents and methods of use thereof for the modulation of angiogenesis
US6919307B2 (en) * 2000-11-01 2005-07-19 Praecis Pharmaceuticals, Inc. Therapeutic agents and methods of use thereof for the modulation of angiogenesis
US7084108B2 (en) * 2000-11-01 2006-08-01 Praecis Pharmaceuticals, Inc. Therapeutic agents and methods of use thereof for the modulation of angiogenesis
US6858580B2 (en) 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
WO2003086178A2 (en) 2002-04-11 2003-10-23 Children's Medical Center Corporation Methods for inhibiting vascular hyperpermeability
ES2398381T3 (es) * 2002-04-11 2013-03-15 Children's Medical Center Corporation Conjugados del copolímero de ácido metacrílico-hpma-tnp-470 y sus usos
CA2550873A1 (en) * 2003-12-29 2005-07-21 Praecis Pharmaceuticals, Inc. Inhibitors of methionine aminopeptidase-2 and uses thereof

Also Published As

Publication number Publication date
JP2005529870A (ja) 2005-10-06
US7332523B2 (en) 2008-02-19
CA2480666A1 (en) 2003-10-23
US20080112919A1 (en) 2008-05-15
US20060020024A1 (en) 2006-01-26
US20040229945A1 (en) 2004-11-18
CA2480666C (en) 2012-03-06
WO2003086382A1 (en) 2003-10-23
EP1494662A4 (en) 2006-07-19
ES2398381T3 (es) 2013-03-15
US20090176874A1 (en) 2009-07-09
AU2003230852A1 (en) 2003-10-27
EP1494662B1 (en) 2012-11-28
EP1494662A1 (en) 2005-01-12
AU2008229857A1 (en) 2008-10-30
AU2003230852B2 (en) 2008-07-10
US20050169881A1 (en) 2005-08-04
US6949584B2 (en) 2005-09-27

Similar Documents

Publication Publication Date Title
JP4514455B2 (ja) Ｔｎｐ−４７０ポリマー複合体及びその使用
Ferber et al. Co-targeting the tumor endothelium and P-selectin-expressing glioblastoma cells leads to a remarkable therapeutic outcome
Zhang et al. Stimulus-responsive nanoscale delivery systems triggered by the enzymes in the tumor microenvironment
CN103687624B (zh) 靶向的聚合缀合物和其用途
CN102105157B (zh) 聚合物、抗血管生成剂和靶向部分的缀合物及其在制备用于治疗骨相关血管生成状况的药物中的用途
US20240033364A1 (en) Castration resistant prostate cancer
KR20160035081A (ko) 생체 내에서 RNAi 유발제를 종양 세포로 전달하기 위한 폴리콘주게이트
US20080248030A1 (en) Method of Treating Angiogenic Diseases
KR102279429B1 (ko) 멀티 암 표적 항암 콘쥬게이트
Japir et al. Tumor-dilated polymersome nanofactories for enhanced enzyme prodrug chemo-immunotherapy
US20090011991A1 (en) Novel Curcuminoid-Factor VIIA Constructs as Suppressors of Tumor Growth and Angiogenesis
US12433857B2 (en) Conjugate and cancer therapeutic agent
Cuchelkar et al. Polymer–drug conjugates
CN114404610B (zh) 透明质酸-香叶醇聚合物前药多生物响应的给药系统HSSG NPs及其制备方法和应用
HK1220397B (zh) 用於在活體中遞送rnai觸發子至腫瘤細胞的聚偶聯物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060224

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060224

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20060224

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090909

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091209

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100113

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100331

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100421

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100511

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130521

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees